Introduction
History
Mechanism of action
Classification
Medication in this class
Medical Uses
Side effect
Monographs
Introduction
Cephalosporins are a class of antibiotics used to treat bacterial infections. They belong to the beta-lactam group of antibiotics, which also includes penicillins .The cephalosporins (and other β-lactams) have the ability to kill bacteria by inhibiting essential steps in the bacterial cell wall synthesis which in the end results in osmotic lysis and death of the bacterial cell. Cephalosporins are widely used antibiotics because of their clinical efficiency and desirable safety profile.
Cephalosporins were first discovered in the 1940s from the fungus Cephalosporium acremonium.
History
Cephalosporin compounds were first isolated from cultures of Acremonium strictum from a sewer in Sardinia in 1948 by Italian scientist Giuseppe Brotzu. He noticed these cultures produced substances that were effective against Salmonella typhi, the cause of typhoid fever, which had β-lactamase. Guy Newton and Edward Abraham at the Sir William Dunn School of Pathology at the University of Oxford isolated cephalosporin C. The cephalosporin nucleus, 7-aminocephalosporanic acid (7-ACA), was derived from cephalosporin C and proved to be analogous to the penicillin nucleus 6-aminopenicillanic acid (6-APA), but it was not sufficiently potent for clinical use. Modification of the 7-ACA side chains resulted in the development of useful antibiotic agents, and the first agent, cefalotin (cephalothin), was launched by Eli Lilly and Company in 1964.
Mechanism of action
The mechanism of action of cephalosporins involves inhibiting bacterial cell wall synthesis, leading to the death or inhibition of bacterial growth.
Here is a step-by-step breakdown of how cephalosporins work:
1. Binding to Penicillin-Binding Proteins (PBPs): Cephalosporins have a similar structure to penicillins, and they target the penicillin-binding proteins (PBPs) present in the bacterial cell wall. PBPs are enzymes that play a crucial role in synthesizing and remodeling the bacterial cell wall.
2. Inhibition of Transpeptidation: Cephalosporins bind to the PBPs, particularly the transpeptidase enzymes. These enzymes are responsible for cross-linking the peptidoglycan strands, a crucial step in the formation and stability of the bacterial cell wall. By binding to the transpeptidase enzymes, cephalosporins prevent the cross-linking process.
3. Impaired Cell Wall Formation: As a result of the transpeptidation inhibition, the formation of the bacterial cell wall is disrupted. The cell wall loses its structural integrity and becomes weak.
4. Activation of Autolytic Enzymes: Cephalosporins also stimulate the activation of autolytic enzymes, such as autolysins, which are naturally occurring enzymes in bacteria. These enzymes break down the existing peptidoglycan in the bacterial cell wall.
5. Cell Lysis and Death: The combination of impaired cell wall synthesis and activation of autolytic enzymes leads to the weakening and eventual lysis (rupture) of the bacterial cell wall. Without a functional cell wall, the bacteria are unable to maintain their shape and integrity, ultimately resulting in cell death.
Classification
Cephalosporins are classified into five generations based on their development and spectrum of activity.
1. First-generation cephalosporins: These cephalosporins have a narrower spectrum of activity and are primarily effective against Gram-positive bacteria, including some strains of Staphylococcus and Streptococcus. Examples include cefazolin and cephalexin.
2. Second-generation cephalosporins: Second-generation cephalosporins have an expanded spectrum of activity compared to first-generation cephalosporins. They retain activity against Gram-positive bacteria and have improved activity against some Gram-negative bacteria. Examples include cefuroxime and cefaclor.
3. Third-generation cephalosporins: Third-generation cephalosporins have an even broader spectrum of activity, particularly against Gram-negative bacteria, including Enterobacteriaceae (such as Escherichia coli and Klebsiella) and Haemophilus influenzae. They also maintain activity against some Gram-positive bacteria. Examples include ceftriaxone and ceftazidime.
4. Fourth-generation cephalosporins: Fourth-generation cephalosporins have a similar spectrum of activity against Gram-negative bacteria as third-generation cephalosporins, but they have increased stability against bacterial enzymes that can break down the antibiotic. They also retain activity against some Gram-positive bacteria. Examples include cefepime.
5. Fifth-generation cephalosporins: Fifth-generation cephalosporins are the most recent addition to the cephalosporin class. They have an expanded spectrum of activity against both Gram-positive and Gram-negative bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and certain Enterobacteriaceae. Examples include ceftaroline and ceftobiprole.
Medications in ths class
Cefprozil
Cefadroxil
Ceftriaxone
Cefaclor
Ceftin(Cefuroxime axetil)
Cefpodoxime
Cephalexin
Cefdinir
Cefazolin
Suprax (Cefixime)
ceftazidime
cefepime
ceftaroline
ceftobiprole
Medical Uses
Cephalosporins can be indicated for the prophylaxis and treatment of infections caused by bacteria susceptible to this particular form of antibiotic.
First-generation cephalosporins are active predominantly against Gram-positive bacteria, such as Staphylococcus and Streptococcus.
They are therefore used mostly for :
skin
soft tissue infections
prevention of hospital-acquired surgical infections.
Successive generations of cephalosporins have increased activity against Gram-negative bacteria, albeit often with reduced activity against Gram-positive organisms.
The antibiotic may be used for patients who are allergic to penicillin due to the different β-lactam antibiotic structure. The drug is able to be excreted in the urine.
Side effects
Common adverse drug reactions (ADRs) (≥ 1% of patients) associated with the cephalosporin therapy include:
diarrhea
nausea
rash
electrolyte disturbances
pain and inflammation at injection site
Infrequent ADRs (0.1–1% of patients) include :
vomiting
headache
dizziness
oral and vaginal candidiasis
superinfection, eosinophilia, nephrotoxicity, neutropenia, thrombocytopenia, and fever.
Monographs